X4 Pharmaceuticals Inc - XFOR STOCK NEWS

X4 Pharmaceuticals (XFOR) has announced a 1-for-30 reverse stock split effective April 28, 2025. The split will reduce outstanding shares from approximately 173.6 million to 5.8 million, with trading on Nasdaq Capital Market beginning on the same date.

This strategic move comes after receiving a Nasdaq deficiency notice on August 13, 2024, due to the stock price falling below the required $1.00 minimum bid for 30 consecutive business days. While X4 received an additional compliance period until August 11, 2025, the reverse split aims to increase the stock price and maintain Nasdaq listing requirements.

The split will proportionally adjust equity incentive plans, stock options, and warrants. Stockholders with fractional shares will receive cash in lieu, and those with book-entry shares will see changes reflected in their accounts after April 28, 2025.

X4 Pharmaceuticals (XFOR) has announced the issuance of inducement awards to new employees under its 2019 Inducement Plan. The awards, effective January 31, 2025, consist of options to purchase 450,471 shares of X4's common stock at an exercise price of $0.2030 per share, matching the closing price on April 22, 2025.

The stock options, granted in accordance with Nasdaq Listing Rule 5635(c)(4), feature a ten-year term and a four-year vesting schedule. The vesting structure includes 25% of shares vesting after 12 months, followed by monthly vesting of the remaining shares over 36 months, contingent on continued employment.

X4 Pharmaceuticals (XFOR) reported its Q4 and full year 2024 financial results, highlighting significant progress in commercializing XOLREMDI® for WHIM syndrome and advancing clinical trials. Key financial metrics include $2.6 million in XOLREMDI® net revenues since its May 2024 launch, and $102.8 million in cash position as of December 31, 2024.

The company's Phase 3 4WARD trial for chronic neutropenia has reached ~90% site activation, with full enrollment expected in Q3/Q4 2025 and top-line data anticipated in 2H 2026. Notable achievements include the sale of a priority review voucher for $105 million and strategic partnerships in EU/ANZ and MENA regions, with Norgine Pharma providing a €28.5 million upfront payment.

Financial results show R&D expenses of $81.6 million and SG&A expenses of $61.5 million for 2024. The company implemented a strategic restructuring in February 2025, expected to reduce annual spending by $30-35 million. X4 projects sufficient funding into first half of 2026.

X4 Pharmaceuticals (XFOR), a company focused on rare immune system diseases, has scheduled its fourth-quarter and full-year 2024 financial results announcement for March 25, 2025. The company will host a conference call and webcast at 8:30 a.m. ET on the same day.

Investors and interested parties can access the conference call by dialing 1-800-267-6316 (US) or 1-203-518-9783 (International) using the conference ID: X4PHARMA. A live webcast will be available through X4's investor relations website, with a replay accessible after the call.

X4 Pharmaceuticals (XFOR) has entered an exclusive distribution agreement with taiba rare for XOLREMDI® (mavorixafor) in seven Middle East countries. XOLREMDI, approved by the FDA in April 2024, is the first and only oral, once-daily treatment for WHIM syndrome in patients 12 years and older.

The agreement covers Saudi Arabia, UAE, Qatar, Oman, Kuwait, Bahrain, and Egypt. taiba will handle distribution, promotion, marketing, and sales within these territories, while collaborating with X4 on strategic decisions. Local regulatory filings will be based on X4's FDA registration dossier. Pending approvals, taiba can provide XOLREMDI through a named-patient program.

XOLREMDI is currently under review by the European Medicines Agency's CHMP and has received Orphan Drug Designation in both the U.S. and EU.

X4 Pharmaceuticals (XFOR) announced a strategic restructuring to optimize its operations and extend cash runway. The company will reduce its workforce by 43 employees (30%), close its Vienna facility, and discontinue research efforts including pre-clinical drug programs. The restructuring aims to focus on advancing mavorixafor for chronic neutropenia treatment while optimizing U.S. promotion of XOLREMDI® for WHIM syndrome.

The company expects to decrease annual spending by $30-35 million and extend its cash runway into the first half of 2026. The workforce reductions are scheduled for completion in Q1 2025. The company maintains its timeline for full enrollment in the global Phase 3 clinical trial for chronic neutropenia by mid-2025.

X4 Pharmaceuticals (XFOR) has announced the issuance of inducement awards to new employees under its 2019 Inducement Plan, effective January 31, 2025. The awards consist of options to purchase 130,117 shares of X4's common stock, granted exclusively to individuals who were not previously X4 employees.

The stock options have a ten-year term and an exercise price of $0.7001 per share, matching X4's closing price on January 31, 2025. The vesting schedule spans four years, with 25% of shares vesting after 12 months and the remaining vesting monthly over the following 36 months, contingent on continued employment. These grants were approved by X4's Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).

X4 Pharmaceuticals (XFOR) announced that its Marketing Authorization Application (MAA) for mavorixafor to treat WHIM syndrome has been validated for review by the European Medicines Agency (EMA). The submission follows the drug's U.S. FDA approval in April 2024 under the brand name XOLREMDI®, an oral, once-daily treatment for patients 12 years and older with WHIM syndrome.

The application is supported by positive results from the global Phase 3 4WHIM clinical trial, which met its primary endpoint and a key secondary endpoint. The trial demonstrated that mavorixafor reduced the rate, severity, and duration of infections in participants and was generally well tolerated with no treatment-related serious adverse events.

If approved, mavorixafor would be the first drug indicated for WHIM syndrome in Europe, targeting an estimated population of 1,000 people. X4 recently announced an exclusive licensing agreement with Norgine to commercialize mavorixafor in Europe, Australia, and New Zealand. A decision on the MAA is expected in the first half of 2026.

X4 Pharmaceuticals (XFOR) has entered into an exclusive licensing agreement with Norgine for the commercialization of mavorixafor in Europe, Australia, and New Zealand. The deal includes a €28.5 million upfront payment and potential regulatory and commercial milestone payments of up to €226 million, plus tiered double-digit royalties up to mid-twenties on future net sales.

Mavorixafor, marketed as XOLREMDI® in the US, is an oral, once-daily treatment for WHIM syndrome patients aged 12 and older. X4 is preparing to submit a Marketing Authorization Application to the European Medicines Agency and is conducting a global Phase 3 trial for chronic neutropenia. Under the agreement, X4 will handle manufacturing and supply, while Norgine will manage market access and commercialization in the licensed territories.